PATENT CLAIM ANALYSIS

Application Number: 15580630
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
The purpose of the present invention is to provide a therapeutic agent that is more effective in refractory amyloidosis. More specifically, it is to provide a novel substance that is highly safe and is more excellent in a TTR protein amyloid fibril formation-inhibiting effect as compared with conventional therapeutic agents. Provided by the invention is an amyloid fibril suppressant comprising as an active ingredient a complex of a conjugate (GUG-β-CDE) of glucuronylglucosyl-β-cyclodextrin (GUG-β-CyD) and polyamide amine dendrimer having an alkylene diamine as the core with RNA that causes RNA interference in the mRNA of transthyretin (TTR). Also provided by the present invention is a pharmaceutical composition comprising the amyloid fibril suppressant for the prevention and/or treatment of amyloidosis.

Claim (Index 22):
The method according to  claim 20 , wherein the amyloidosis is familial amyloid polyneuropathy (FAP), Alzheimer's disease, senile systemic amyloidosis (SSA) or AA amyloidosis, and the RNA is shRNA or siRNA.

Metadata:
- Claim Count in Document: 43.0
- Percentile: 93.0
- Lexical Diversity: 1.74324
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13974761', '15736826', '13303060', '11256026', '11527020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7785537974472481
- 35 USC 102 Novelty (BERT): 0.4908409606294696
- Combined Prediction Score: 0.7497825137654702
- Mean Citation Score: 218.558204
- Max Citation Score: 240.02737
- Similarity Product: 192.7288381076348

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test